Monkeypox: Clinical Overview

Nick Gilpin, DO, FACP, FIDSA Medical Director, Infection Prevention Beaumont Health




History & Epidemiology

- First human case in 1970
- Endemic in several African countries
 - Outbreaks have occurred sporadically around the world, including the US almost always travel-related
- The source of the virus is not well known (not monkeys) possibly African rodents or other non-human primates
- Two clades responsible for disease: Clade I and Clade II
 - Infections in the current outbreak are due to Clade II
 - Clade II infections are generally less severe than Clade I



Current monkeypox situation, worldwide

- More than 53,000 cases reported worldwide
 - Highest number of reported cases in US
- Cases currently flattening or decreasing in many regions





Transmission

- Person-to-person via direct contact (including intimate contact)
 - Includes contact with lesions, scabs, and/or body fluids
 - Capable of spreading until the rash is healed
 - Role of asymptomatic transmission? Possible transmission, but not well understood
- Contact with fomites and infectious surfaces, such as clothing, sheets, etc.
- Respiratory secretions
 - From prolonged face-to-face contact (e.g., kissing, etc.)
 - Less common route of transmission
- Is monkeypox a sexually transmitted disease?
 - Monkeypox can spread via close physical contact, such as sex, but insufficient evidence of transmission through genital fluids
- Can animals/pets harbor monkeypox?
 - Yes all mammals should be considered susceptible to monkeypox and capable of becoming infected




Signs and Symptoms

- Incubation period: 3 to 17 days
- Classic: prodromal symptoms (fever, lymphadenopathy, flu-like illness) followed by a characteristic rash (lesions at same stage)
- Current outbreak: mix of classic presentation plus atypical features
 - Rash often in genital or perianal regions, may be minimal pox present
 - Often confused with other infections (syphilis, HSV, etc.)
 - Prodromal symptoms may be mild or absent
- Duration of symptoms ranges from 2-4 weeks
- Most disease is mild; hospitalization and death are rare, even in immunocompromised hosts



Reported symptoms

- Per recent NEJM report:
 - 528 infections diagnosed 4/27 to 6/24 at 43 sites in 16 countries
 - Cases predominantly seen among gay, bisexual men (98%)
 - Transmission likely occurred through sexual activity (95%)
 - 95% of the persons presented with a rash (64% having ≤10 lesions), 73% had anogenital lesions, and 41% had mucosal lesions (with 54 having a single genital lesion)



Monkeypox: images



Source: NYTimes.com




Source: New York Post



Source: statnews.com




Current cases by age/gender, USA



23,893 total confirmed monkeypox/orthopoxvirus cases as of September 19




Current cases by race/ethnicity (weekly), USA





Current cases by onset date, MI

- Confirmed cases as of 9/20: 257
- 60% Age 25-39
- 98% Male
- 59% Black, 35% White
- 91% MSM
- 54% HIV positive





Infection Prevention

- Hand hygiene
- Patient placement: single private room with door closed
 - Special air handling not required
- Wear appropriate PPE when with the patient (including while collecting specimens for suspected cases)
 - Gown, gloves, eye protection, N95 or higher respirator
- Standard cleaning and disinfection practices
- Patients isolating at home should avoid contact with others including pets
 - Keep rash covered to avoid contamination of surfaces
- Duration of precautions: until infection is ruled out, or until all lesions have healed (2-4 weeks)



Diagnosis

- Swab of lesion or scab for PCR testing = gold standard
 - Sample collection may vary somewhat based on lab standards contact your reference lab or local health department if questions on how to collect an adequate specimen
- Results usually available within 1-4 days



Treatment: whom to treat

- Consider treatment for the following:
 - People with severe disease (hospitalization, sepsis, encephalitis, etc.)
 - People with risk of progression to severe disease (immunocompromised hosts, children < 8 y/o, pregnant women, people with other disease complications)
 - People with monkeypox in areas that may constitute a special hazard, or may increase transmission risk to others (genitals, anus)

Treatment

- Tecovirimat (TPOXX)
 - May shorten duration of illness/shedding, decrease mortality
 - FDA-approved for smallpox, available for monkeypox treatment via IND protocol
 - 2-week course of treatment available PO or IV
 - Low risk of adverse events: most common are headache and nausea
- Other treatment options (limited data on efficacy):
 - Vaccinia immune globulin, Cidofovir, Brincidofovir
- Median age of patients receiving TPOXX = 35.7 years



Vaccination (PEP/PrEP)

 JYNNEOS and ACAM2000 are the two vaccines that may be used for the prevention of monkeypox disease

JYNNEOS:

- Live, replication-deficient Vaccinia vaccine (cannot cause monkeypox or smallpox)
- 2-dose series given at day 0, 28; given subcutaneously or intradermally
- Peak immunity after 2 weeks, duration of protection unknown
- Efficacy: "about 85%," but data lacking
- AEs: most common include pain, redness, swelling at injection site
- If given for PEP, should be given as soon as possible after known or high-risk exposure

ACAM2000:

- Single dose percutaneous administration less widely available
- Does having smallpox vaccination years ago prevent monkeypox?
 - Not clear may be some residual protection, but breakthrough cases of monkeypox have been reported in persons vaccinated against smallpox



Obtaining treatment or vaccine

- First, determine patient eligibility
- Next, contact your local health department
 - Most have treatment or vaccine or both available and can help administer
- Alternatively, check with your affiliated healthcare systems
 - Many healthcare systems may have processes in place to obtain treatment and/or vaccine for PEP/PrEP

 IND forms required for treatment can be obtained on the CDC website and can be submitted <u>after</u> treatment begins

Thank You

Nicholas.Gilpin@beaumont.org